Allergy Therapeutics (LON:AGY) Stock Price Down 11.3% – Here’s What Happened

Allergy Therapeutics plc (LON:AGY)’s share price dropped 11.3% during mid-day trading on Wednesday . The company traded as low as GBX 5.40 and last traded at GBX 5.50. 370,638 shares changed hands during trading, an increase of 39% from the average daily volume of 266,926 shares. The stock had previously closed at GBX 6.20.

Allergy Therapeutics Trading Down 11.3%

The company has a debt-to-equity ratio of 629.58, a quick ratio of 1.48 and a current ratio of 1.13. The firm has a fifty day moving average price of GBX 7.91 and a 200 day moving average price of GBX 9.86. The company has a market cap of £348.29 million, a price-to-earnings ratio of -5.67, a P/E/G ratio of -30.70 and a beta of 0.87.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.